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Rationale Recurrent stroke is prevalent in both developed and
developing countries, contributing significantly to disability
and death. Recurrent stroke rates can be reduced by adequate
risk factor management. However, adherence to prescribed
medications and lifestyle changes recommended by physicians
at discharge after stroke is poor, leading to a large number
of preventable recurrent strokes. Using behavior change
methods such as Motivational Interviewing early after stroke
occurrence has the potential to prevent recurrent stroke.
Aims and/or hypothesis The overall aim of the study is to
determine the effectiveness of motivational interviewing in
improving adherence to medication and lifestyle changes rec-
ommended by treating physicians at and after hospital dis-
charge in stroke patients 12 months poststroke to reduce risk
factors for recurrent stroke.
Design Recruitment of 430 first-ever stroke participants will
occur in the Auckland and Waikato regions. Randomization
will be to intervention or usual care groups. Participants ran-
domized to intervention will receive four motivational inter-
views and five follow-up assessments over 12 months.
Nonintervention participants will be assessed at the same time
points.
Study outcomes Primary outcome measures are changes in
systolic blood pressure and low-density lipoprotein levels 12
months poststroke. Secondary outcomes include self-reported
adherence and barriers to prescribed medications, new cardio-
vascular events (including stroke), changes in quality of life,
and mood.
Discussion The results of the motivational interviewing in
stroke trial will add to our understanding of whether motiva-
tional interviewing may be potentially beneficial in the man-
agement of stroke and other diseases where similar lifestyle
factors or medication adherence are relevant.
Key words: adherence, motivational interviewing, recurrent stroke,
secondary prevention
Introduction
Strokes recur in 6–25% of people (1–3), usually in the first year
(1,4,5). The risk of stroke is highest early after the event (4). By
five-years poststroke, the cumulative risk of recurrent stroke is
30–40% (5). Recurrent stroke may lead to greater disability, insti-
tutionalization, increased risk of dementia, and a high risk of
death (6), and therefore, poorer health and economic outcomes
(7).
Management strategies for secondary stroke prevention are
well established (2,3,5,7–10), yet remain underutilized (8,11). The
landmark INTERSTROKE studies suggest that 10 risk factors are
associated with 90% of the risk of first-ever stroke (12). Recurrent
strokes are largely preventable using similar strategies to that of
primary stroke prevention (13). Several trials have attempted to
improve secondary prevention of stroke and coronary heart
disease through education of patients and/or caregivers (14,15)
and improving access to care (16–20). However, these have not
improved management of clinical or behavioral risk factors (14–
19,21,22), required complex computer systems (20), or were
designed for inpatients only (21,22). In a systematic review, life-
style modifications were shown to be effective for secondary
stroke prevention with improvements seen in both lifestyle
behavior changes and physiological outcomes (23). A recent study
suggests that long-term adherence to nonspecific prescription
pills reduced the risk of subsequent vascular events in persons
who had a recent ischemic stroke (24). Although adherence to
prescribed medications and/or recommendations to lifestyle
changes (such as reducing smoking, increasing physical activity)
after first stroke are effective strategies to reduce recurrent stroke,
in practice, the implementation of these recommendations is
poor (25,26). Targeting adherence may be a key to reducing the
incidence of recurrent stroke; therefore, it is both appropriate and
timely to conduct trials to assess whether new approaches may
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improve patient adherence to evidence-based guidelines for sec-
ondary stroke prevention (10,27) after hospital discharge.
Motivational interviewing (MI) is a structured, patient-focused
(28–33), and cost-effective (34) intervention that was originally
developed for the treatment of people with problem drinking,
addictions (35,36), and substance abuse management (32,37–40)
but has been increasingly used in other areas of medicine (41,42),
including stroke (43–47), traumatic brain injury (48), and cardio-
vascular disease (49–51). The objective of MI is to help the client
to explore their ambivalence towards behavior change, and by
resolving this ambivalence, facilitating positive behavior change
in the individual (42).
A significant benefit of MI on mood early after stroke over
usual stroke care was recently demonstrated in a randomized
controlled trial (43). Given the evidence for efficacy and cost
effectiveness of MI for behaviour change, this intervention has
been identified as a high research priority (41,52). However, the
majority of trials have been relatively small and no studies have
been carried out specifically to test the effectiveness of MI in
reducing risk factors related to recurrent stroke. Therefore, a large
randomized clinical trial is needed to provide clarity on how MI
applies to recurrent stroke. Given its potential to encourage
patients to adhere to medication and lifestyle changes recom-
mended by clinicians, this trial is designed to assess the effective-
ness of MI in reducing outcomes related to recurrent stroke.
Objectives
The overall aim of the study is to determine the effectiveness of
MI in improving adherence to medication and lifestyle changes
recommended by treating physicians at and after hospital dis-
charge in stroke patients 12 months postrandomization.
Methods
Trial design
This is a phase III single-blind randomized controlled trial of
participants with first-ever stroke (excluding subarachnoid hae-
morrhage) followed for 12 months after randomization. Partici-
pants are randomized to either the MI intervention group
(henceforth referred to as MI) or usual care (UC). Recruitment
for the trial commenced on March 1, 2011 with the population-
based ARCOS IV Incidence and Outcomes Study (53). Figure 1 is
a flowchart of the overall trial design of the MIST study.
Patient population- inclusion and exclusion criteria
All consecutive adult (16 years or older) stroke survivors who had
a first-ever stroke and are residents of Auckland or Waikato
Region are considered potentially eligible for inclusion in the trial.
Stroke is defined according to the World Health Organization
definition as ‘rapidly developing clinical signs of focal (or global)
disturbance of cerebral function, with symptoms lasting 24 hours
or longer or leading to death, with no apparent cause other than
of vascular origin’ (54). A diagnostic review committee compris-
ing four stroke neurologists meet fortnightly to confirm the diag-
nosis of stroke and classification of all ischemic cases. The
committee uses medical history, hospital discharge summaries,
clinical and laboratory findings (including vascular and cardiac
imaging), or necropsy results when available to inform their deci-
sions. A detailed description of the diagnostic review process is
available in the article describing the methodology of the ARCOS
IV Incidence and Outcomes Study (53).
The main exclusion criteria are (1) recurrent stroke (excluding
clinically silent previous strokes); (2) a diagnosis of subarachnoid
haemorrhage; (3) significant impairments precluding participa-
tion (e.g. aphasia); (4) inability to give informed consent;
(5) another condition likely to impact their participation in the
trial (e.g. life-threatening condition other than cardiovascular
disease); and (6) expected discharge to hospital/nursing home
setting where adherence to lifestyle recommendations and medi-
cations is beyond participant control.
Ethical approval and trial registration
The study was given ethical approval by the Northern X Regional
Ethics Committee for experiments in human subjects and the
Auckland University of Technology Ethics Committee. The trial is
registered with the Australian New Zealand Clinical Trial Registry
(Trial Registration Number: ACTRN 12610000715077).
Recruitment
Between March 1, 2011 and February 29, 2012, potential partici-
pants were recruited for the trial from the main ARCOS IV Inci-
dence and Outcomes study (53). Participants eligible for ARCOS
IV were approached for participation in the MIST study during
the period of recruitment for ARCOS incidence study. Additional
participants were recruited from the Waikato region for the same
period. From March 1, 2012, participants will be recruited from
all four Auckland public hospitals, and the recruitment period is
expected to continue up to December 2013. Daily searches of
admissions data are carried out in all four Auckland region public
hospitals for records suggestive of a diagnosis of first-ever stroke.
Informed consent
Potentially eligible participants are identified by a hospital-based
research assistant (RA) via regular checks of each hospital data-
base for new admissions and participation at weekly medical and
diagnostic team meetings for relevant hospital wards/units.
Potential participants are approached by an RA to give informed
consent to participate. If consent is obtained, baseline case record
forms (CRFs) will be completed.
Screening
All participants who meet the main inclusion criteria and provide
informed consent undergo a face-to-face detailed screening
process with a study RA to ensure that they meet the eligibility
criteria for randomization into the trial. Table 1 shows the eligi-
bility screening criteria used to identify participants eligible for
randomization. Information from medical records is also used
when available to aid the screening process. After completion of
eligibility screening, participants identified as meeting the eligi-
bility criteria are randomized.
Randomization
Eligible study participants are randomized to either the MI or UC
groups using web-based computerized randomization software. A
stratified minimization algorithm is used to randomize partici-
pants in order to balance possible prognostic factors [i.e. age (<70,
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70+), stroke severity (Barthel Index <18 and ≥18), gender and
race-ethnicity (European, non-European)] across the two groups.
Following randomization, a confirmation letter is sent to the
study participant that includes a reminder of the timing of
primary outcome measures requested for the purpose of the study
(blood pressure and blood lipid cholesterol levels at 12 months
after stroke). A reminder letter is also sent to the participant, along
with a blood request form for a free blood lipid test, one-month
prior to the 12 month assessment date. In addition, a letter is sent
to the participant’s General Physician (GP) to inform them of
their patients’ participation in the trial and as a reminder of the
New Zealand Clinical Guidelines for Stroke Management recom-
mendations to routinely monitor blood pressure and blood lipid
levels in stroke patients. The letter includes a request for access to
Confirm eligibility for MIST
Approach for
consent to MIST
Informed consent 
gained
Decline
Randomisation
(within 6 weeks post-stroke)
28 Day Follow-up assessment
Note: all time frames are in months post-stroke 
*MI: Motivational Interviewing
Deceased Eligible
Complete Baseline participant details 
and Contact Details 
Obtain referral from hospital medical records
for identifying stroke cases
MIST Eligibility Screen
No further 
action
Not 
Eligible
Eligible
Motivational 
Interviewing 
(MI) Group
Usual Care 
(UC) Group
3 Month Follow-up assessment
6 Month Follow-up assessment
9 Month Follow-up assessment
12 Month Follow-up assessment
First MI*
28 Days
Second MI
3 Months
Third MI
6 Months
Fourth MI
9 Months
Deceased or 
hospitalisation 
check
Notification of SAE to Data 
Safety Monitoring Committee
Fig. 1 Flowchart of motivational interviewing in stroke (MIST) study procedures.
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these measures by our research team at relevant study time points
if required.
Blinding
To reduce measurement bias, follow-up assessments are carried
out by individual community-based RAs who are blind to the
treatment allocation of the participant and not involved in the
delivery of the intervention. At the time of recruitment to
the study and prior to each follow-up assessment, study partici-
pants are requested not to disclose their group allocation by men-
tioning any contact with the motivational interviewer to the RA
conducting the assessment. Compliance to group allocation
blinding will be monitored by the study manager, and reports of
unblinding either by participants or research assistants will be
recorded as protocol violations, and steps are taken to ensure
future assessments are conducted by a blinded assessor for any
unblended participants.
MI intervention
The trial intervention is based on the principles of MI as
described by Miller and Rollnick (32). To assist the interviewers in
adhering to a standardized approach and format when conduct-
ing the intervention, an intervention manual has been developed
providing guidance for each of the intervention time points and
appropriate tools to assist in the interviewing process.
MI interviews are conducted at 28 days, three-, six-, and nine-
months poststroke (see flowchart Fig. 1). The first interview is
conducted individually face to face. Subsequent interviews are
conducted over the telephone whenever possible. MI interviews
are to be conducted by an RA who has undergone training in MI
and has an understanding of good clinical practice in research.
Researchers conducting the interventions are provided with train-
ing on the principles of MI by an experienced trainer who is able
to demonstrate relevant experience and expertise in this area. RAs
were additionally provided training on stroke risk factors, such as
diet and nutrition, and medications. As per principles of MI,
standard information on cardiovascular disease risk and preven-
tion from the New Zealand Heart Foundation was provided to
participants only at their request. Ongoing training and feedback
are provided to the MI interviewers throughout the study at
regular group and individual training sessions. All training mate-
rial is saved electronically for future reference. Interviews con-
ducted with participants are recorded, and the de-identified
electronic files are available for review by the interviewers and
trainer. Ongoing monitoring of the quality and consistency of the
MI across all RAs is regularly provided by the MI trainer.
Primary outcomes
Primary outcome measures are (1) change in systolic blood pres-
sure (SBP) and (2) low-density lipoprotein (LDL)-cholesterol
levels at 12 months poststroke.
Secondary outcomes
Secondary outcome measures are (1) self-reported adherence
to prescribed medications, including self-reported use of
antiplatelet/anticoagulant medications, statin, and blood
pressure-lowering therapy medications as prescribed (and cross-
checked with electronic medication dispense records, where avail-
able); (2) self-reported barriers to adherence to medications;
(3) cardiovascular events (new stroke or coronary heart disease,
both fatal and nonfatal); (4) quality of life as measured by the
SF-36 (56); (5) mood as measured by the Hospital Anxiety and
Depression Scale (57); (6) change in other blood lipid levels
(HDL-cholesterol, total cholesterol, and triglycerides); (7) physi-
cal disability as measured by the Barthel Index (58) at 12 months;
and (8) healthcare resource consumption and cost effectiveness of
the intervention.
Outcome assessments (Table 2) are carried out at 28 days,
three-, six-, nine- and 12 months following stroke, with the
primary outcome assessment for SBP and LDL-cholesterol
carried out at 12 months poststroke. Blood pressure measure-
ments are carried out at six- and 12-month assessments at the
participants’ place of residence.
Withdrawals and loss to follow-up
Participants are able to withdraw their involvement in the study at
any time. The ‘intention-to-treat’ principle will apply for partici-
pants who withdraw from the study or are lost to follow-up, so
that data from up to and including their last completed assess-
ment will be included in the analyses.
Data management
Data management services including statistical analyses are con-
tracted to the National Institute for Health Innovation, The Uni-
versity of Auckland. De-identified participant details and data
from CRFs are entered into a web-based password-protected
database managed by the data management team. All participants
Table 1 Eligibility screening criteria
Criteria Eligibility requirement for inclusion
Diagnosis First-ever stroke, not subarachnoid hemorrhage
Date of stroke Randomization within six-weeks poststroke
Cognitive impairment Mini-Mental State Examination (55) ≥23
Mental Health No current mental health diagnosis and/or receiving current psychological treatment that would affect/contradict
motivational interviewing
Involvement in other studies? No involvement in another study that could affect compliance with treatment or result in significant participant
burden
Access to telephone Has telephone access
Availability Available to answer further questions in up to 12 months postrandomization
English language Able to converse fluently in English
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in the study are allocated a unique registration number electroni-
cally generated by the database. Paper copies of CRFs and any
supporting documentation (including hospital discharge sum-
maries and other relevant medical reports) are de-identified and
stored securely, with identifying contact details and signed
consent forms stored separately, for seven-years.
Data safety monitoring
An independent Data Safety Monitoring Committee (DSMC) has
been established to safeguard the interests of the trial participants,
assess the safety and efficacy of the intervention during the trial,
and monitor the overall conduct of the clinical trial. The DSMC
provides recommendations about stopping or continuing the trial
in the event of harm or undue risk to study participants. The
DSMC may also make recommendations relating to the recruit-
ment or management of participants, improving adherence to
good clinical practice and procedures for data management and
quality control. The DSMC group meets on an annual basis or
more frequently if the need arises.
Sample size
Four hundred and thirty participants are required to provide 85%
power at α = 0·05 (two sided) to detect a 0·25 mmol/l difference
in LDL-cholesterol (SD 0·8 mmol/l), and 80% power to detect a
4 mmHg difference in SBP (SD 14 mmHg), respectively, between
UC and MI groups, assuming 10% loss to follow-up.
Statistical analyses
All statistical analyses will be performed using sas version 9·3
(SAS Institute Inc., Cary, NC). All tests of significance will be two
tailed and at 5% significance level throughout the analyses. Base-
line characteristics will be summarized and descriptive summary
statistics provided for each treatment group. The distribution of
all continuous outcomes will be assessed for normality, and
skewed data will be subjected to an appropriate transformation
before analysis. Continuous data will be analyzed using multiple
linear regression if normally distributed and nonparametric
analysis if not normally distributed. The change from baseline in
each of the repeated continuous outcomes will be analyzed using
mixed models and adjusted for baseline value and covariates such
as presence of depression as appropriate. Simple incidence rates,
relative and absolute risks, and their respective 95% confidence
intervals will be calculated for all binary outcomes, and the treat-
ment groups will be compared using chi-squared tests with mul-
tiple logistic regression analysis adjusting for other variables as
appropriate. In order to check the validity of the missing at
random (MAR) assumption, baseline characteristics of those par-
ticipants with available data and those participants missing data
will be compared. The primary analyses will be carried out on an
intention to treat basis and mixed models are robust to data that
are MAR (55). A per-protocol analysis will be performed to check
the robustness of the results where participants with any major
protocol violations such as cross-over treatments, withdrawals,
and lost to follow-up will be excluded. The consistency of effects
for major ethnic subgroups (Ma¯ori, Pacific Island, New Zealand
Europeans) will also be assessed using tests for heterogeneity.
Cost effectiveness
The cost effectiveness of the study will be determined by compar-
ing the costs and outcomes associated with the control group with
the group provided with MI. The costs will include the direct
healthcare costs (e.g. hospitalizations, rehabilitation, primary care
and outpatient visits, home help and support, and medications).
Information on health service utilization is being measured
through patient questionnaires and electronic data sources (e.g.
medical databases such as the Patient Management System, Acci-
dent Compensation Corporation, and Ministry of Health data-
bases matched by individual National Health Index number). In
addition, the cost of delivering the intervention will be monitored
using a resource-based costing approach that measures the inputs
required to deliver the program (e.g. identify time required to
recruit, prepare, and deliver the programme, time required
to coordinate the care with other providers, distance travelled to
deliver the program, etc) and then applying market prices to each
of these resources (e.g. cost per hour for the therapist including
50% overheads). This will provide an estimate not only of the net
costs associated with the intervention, but also the cost to other
organizations interested in adopting MI as part of their standard
practice.
Table 2 Outcome measures and timing of follow-up
Baseline* Three-months Six-months Nine-months 12 months
From medical notes:
Demographics (e.g. age, race-ethnicity) ✓
Type of stroke, stroke severity ✓
Prestroke lifestyle risk factors (e.g. smoking, physical activity) ✓
Medical/cardiovascular history ✓
Blood lipid profile ✓ ✓
Blood pressure ✓ ✓ ✓
Telephone interview
Short Form-36 (SF-36) ✓ ✓ ✓ ✓ ✓
Barthel Index (BI) ✓ ✓
Hospital Anxiety Depression Scale (HADs) ✓ ✓ ✓ ✓ ✓
Costs (direct healthcare expenditures) ✓ ✓ ✓
Self-reported adherence and barriers to prescribed medications ✓ ✓ ✓ ✓ ✓
Modification of lifestyle risk factors ✓ ✓ ✓ ✓ ✓
*Baseline assessments are carried out at 28 days poststroke.
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Because the intervention is ultimately aimed at reducing the
risk of stroke recurrence, the primary outcome variable will be the
Quality Adjusted Life Years associated with patients in each arm of
the study. Utility scores will be assessed using the EuroQOL 5D,
and economic modeling using a Markov Modelling in (TreeAge
Pro Suite) 2012 software (TreeAge Software Inc, Williamstown,
MA) will estimate the incremental cost effectiveness of the MI
group compared with UC by estimating the probability of recur-
rent stroke based on their SBP and LDL-cholesterol levels at 12
months poststroke. Modeling will be used to extrapolate resource
usage (given health services usage and health status) and evalu-
ated over the lifetime of the cohort. Probabilistic sensitivity (using
Monte Carlo simulations) analysis will be conducted to reflect the
combined implications of uncertainty in the model parameters.
Further threshold analysis will be performed to identify under
what conditions MI treatment poststroke could be cost effective.
Study organization and funding
The study is hosted at the National Institute for Stroke and
Applied Neurosciences at AUT University, Auckland New
Zealand. The research is funded by the Health Research Council
of New Zealand.
Summary
The MIST study is a randomized clinical trial designed to test the
effectiveness of MI for the secondary prevention of stroke. To the
best of our knowledge, this is one of the largest clinical trials of MI
to be carried out at a population level. This intervention has the
potential benefits of being adapted in the community as a cost
effective means of reducing stroke burden. In addressing the
values and goals of individuals after stroke, MI may present a
multifactorial approach to concomitant reduction of risk factors.
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